T. Rowe Price Investment Management
IMRX icon

T. Rowe Price Investment Management’s Immuneering IMRX Stock Holding History

T. Rowe Price Investment Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-458,233
Closed -$2.22M – 557
2022
Q4 		$2.22M Hold
458,233
– – ﹤0.01% 536
2022
Q3 		$6.56M Buy
+458,233
New +$3.64M 0.01% 517

Other funds holding IMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

T. Rowe Price Investment Management's IMRX Position: Q1 2023 in Review

T. Rowe Price Investment Management sold out of Immuneering (IMRX) in Q1 2023, closing a stake of 458,233 shares — an estimated $2.22M sold.

T. Rowe Price Investment Management first reported a position in IMRX in Q3 2022 and held it in 2 quarters. The position peaked at $6.56M in Q3 2022. 34 funds tracked by Wall St. Rank hold IMRX as of Q1 2023.

  • T. Rowe Price Investment Management reported no remaining Immuneering position as of Q1 2023 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 458,233 Immuneering shares in Q1 2023, an estimated $2.22M.
  • T. Rowe Price Investment Management first reported a position in Immuneering in Q3 2022 and held it in 2 quarters.
  • T. Rowe Price Investment Management's Immuneering position peaked at $6.56M in Q3 2022.
  • 34 funds tracked by Wall St. Rank held Immuneering as of Q1 2023.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2023, filed 15 May 2023.